It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neutrophil extracellular traps (NETs) are web-like structures consisting of DNA, histones and granule proteins, released from neutrophils in thrombus formation, inflammation, and cancer. We asked if plasma levels of the NET markers myeloperoxidase (MPO)-DNA and citrullinated histone H3 (H3Cit)-DNA, are elevated in liver cirrhosis and hepatocellular carcinoma (HCC) and if the levels correlate with clinical parameters. MPO-DNA, H3Cit-DNA, and thrombin–antithrombin (TAT) complex, as a marker of coagulation activity, were measured using ELISA in plasma from 82 patients with HCC, 95 patients with cirrhosis and 50 healthy controls. Correlations were made to clinical parameters and laboratory data and patients were followed for a median of 22.5 months regarding thrombosis development. H3Cit-DNA was significantly (p < 0.01) elevated in plasma from cirrhosis (66.4 ng/mL) and HCC (63.8 ng/mL) patients compared to healthy controls (31.8 ng/mL). TAT levels showed similar pattern (3.1, 3.7, and 0.0 µg/mL respectively, p < 0.01). MPO-DNA was significantly (p < 0.01) elevated in cirrhosis patients (0.53 O.D.) as compared to controls (0.33 O.D.). Levels of MPO-DNA and H3Cit-DNA correlated positively with Child–Pugh and MELD score. TAT was increased in all Child–Pugh and MELD groups. In multivariable logistic regression, Child B and C liver cirrhosis were independent predictors of elevated H3Cit-DNA in plasma. Levels of MPO-DNA and H3Cit-DNA were similar in patients with or without history of thrombosis, or thrombus formation during follow-up. In conclusion, plasma markers of NET formation are elevated in liver cirrhosis and correlate to the degree of liver dysfunction in patients with liver cirrhosis and/or HCC. The presence of HCC did not further increase the plasma levels of NET markers as compared to patients with cirrhosis only.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Karolinska University Hospital, Department of Clinical Chemistry, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Laboratory Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska Institutet, Department of Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
2 Danderyd Hospital, Division of Gastroenterology, Department of Specialized Medicine, Stockholm, Sweden (GRID:grid.412154.7) (ISNI:0000 0004 0636 5158); Karolinska Institutet Danderyd Hospital, Department of Clinical Sciences, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
3 Karolinska Institutet, Division of Pediatrics, CLINTEC, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Astrid Lindgren Children’s Hospital, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Coagulation Unit, Department of Hematology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
4 Karolinska Institutet, Karolinska University Hospital, Division of Surgery, Department of Clinical Science, Intervention and Technology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
5 Karolinska Institutet Danderyd Hospital, Department of Clinical Sciences, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Coagulation Unit, Department of Hematology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
6 Karolinska Institutet Danderyd Hospital, Department of Clinical Sciences, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Danderyd Hospital, Department of Internal Medicine and Infectious Diseases, Stockholm, Sweden (GRID:grid.412154.7) (ISNI:0000 0004 0636 5158)
7 Karolinska Institutet, Department of Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Division of Hepatology, Department of Upper GI Diseases, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)